US › Healthcare

Dare Bioscience Inc (DARE)

US · Healthcare · Biotechnology

$1.34+4.69%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$152,455
Revenue YoY
+499.6%
Net profit
$-3.0M
Profit YoY
+31.5%
EPS
$-0.20
EPS estimate
$-0.30
Net margin
-1,967.7%

EPS came in at -0.20 against a street estimate of -0.30 — a beat of 33.3%.

Key statistics

Market cap
$18.3M
Forward P/E
1.3
P/B
24.90
Book value
$0.05
EPS (TTM)
$-0.91
52-week high
$3.78
52-week low
$1.13
50-day MA
$1.93
200-day MA
$1.94
Beta
1.05

Analyst view

Analysts rate Dare Bioscience Inc a buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $9.67.

Shareholding

Insiders
8.55%
Institutions
8.43%

Largest institutional holders

FundStake
Vanguard Capital Management, LLC3.09%
Geode Capital Management, LLC1.19%
U.S. Bancorp0.61%
Vanguard Fiduciary Trust Co0.44%
UBS Group AG0.29%
State Street Corp0.16%
XTX Topco Ltd0.15%
Susquehanna International Group, LLP0.11%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Dare Bioscience Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.